Introduction
Patients and Methods
Setting and samples
Application and technique of PleuraSeal™ Lung Sealant System
Clinicopathological Parameters
Variablea
| Overall | PleuraSeal™ Group | Control Group |
p-valueb
|
---|---|---|---|---|
40 | 20 | 20 | ||
Age (yrs.), mean (SD)
| 69 (45-82) | 66 (47-81) |
0.34
| |
Gender
| ||||
Male | 31 (77%) | 14 (70%) | 17 (85%) | |
Female | 9 (22%) | 6 (30%) | 3 (15%) |
0.45
|
Chronic lung disease
|
22
|
11
|
11
| |
COPD | 19 (47%) | 9 (45%) | 10 (50%) | |
Lung emphysema | 2 (5%) | 2 (10%) | 0 (0%) | |
Asthma | 1 (2%) | 0 (0%) | 1 (5%) |
0.58
|
Pulmonary function
c
| ||||
FEV1 actual (Ø %), mean (SD) | 85.5 (17.9) | 87 (20.2) | 84 (15.6) |
0.51
|
FEV1 predicted (Ø %), mean (SD) | 65.5 (16.2) | 69 (17.6) | 62 (14.8) |
0.18
|
DLCO actual (Ø %), mean (SD) | 70.5 (14.5) | 70 (15.7) | 71 (13.3) |
0.84
|
DLCO predicted (Ø %), mean (SD) | 55 (14.6) | 56 (16.3) | 54 (12.9) |
0.55
|
Neoadjuvant therapy
|
1
|
0
|
1
| |
Radiation | 0 (0%) | - | - |
NA
|
Chemotherapy | 1 (2%) | 0 (0%) | 1 (5%) |
1.00
|
Concomitant disease
|
23
|
14
|
9
| |
Diabetes | 7 (17%) | 4 (20%) | 3 (15%) |
1.00
|
Othersd
| 16 (40%) | 10 (50%) | 6 (30%) |
0.23
|
Smoking behaviour
| ||||
Current Smoker | 15 (37%) | 8 (40%) | 7 (35%) | |
Ex smoker (≥12 month) | 13 (32%) | 6 (30%) | 7 (35%) | |
Never smoked | 12 (30%) | 6 (30%) | 6 (30%) |
0.14
|
Variablea
| Overall | PleuraSeal™ Group | Control Group |
p-valueb
|
---|---|---|---|---|
40 | 20 | 20 | ||
Surgical diagnosis
| ||||
Lung cancer | 38 (95%) | 18 (90%) | 20 (100%) | |
Lung metastasis | 2 (5%) | 2 (10%) | 0 (0%) |
0.48
|
Operation time (hh:mm)
| 02:35 | 03:07 |
0.07
| |
Lung tissue quality
|
20
|
20
| ||
Normal | 21 (52%) | 10 (50%) | 11 (55%) | |
Fragile | 19 (47.5%) | 10 (50%) | 9 (45%) |
1.00
|
Procedure
| ||||
Right lobectomy
|
19 (47.5%)
|
7 (35%)
|
12 (60%)
| |
Upper | 13 (32%) | 6 (30%) | 7 (35%) | |
Middle | 0 (0%) | 0 (0%) | 0 (0%) | |
Lower | 6 (15%) | 1 (5%) | 5 (25%) | |
Left lobectomy
|
18 (45%)
|
11 (55%)
|
7 (35%)
| |
Upper | 10 (25%) | 7 (35%) | 3 (15%) | |
Lower | 8 (20%) | 4 (20%) | 4 (20%) | |
Segmentectomy
|
2 (5%)
|
1 (5%)
|
1 (5%)
| |
Bilobectomy
|
1 (2.5%)
|
1 (5%)
|
0 (0%)
|
0.26
|
Intraoperative air leaks characteristics
| ||||
Intraoperative leak free (in %) | 100% | 0% |
<0.001
| |
Postoperative leak free (in %)c
| 95% | 15% |
<0.001
| |
Initial # of intraoperative air leaks/patient (Ø)d
| 1.6 | 1.6 | 1.6 |
1.00
|
Initial grade of air leaks/patient | 1.35 | 1.3 | 1.4 | 0.77 |
Additional procedure for air leak control
|
8
|
2
|
6
| |
Suture | 8 (20%) | 2 (10%) | 6 (30%) |
0.23
|
Staple | 0 (0%) | - | - |
NA
|
Efficacy and safety endpoints
Statistical analyses
Results
Trial treatment and control group
Variablea
| PleuraSeal™ Group | Control Group |
p-valueb
|
---|---|---|---|
20
|
20
| ||
Adjusted air leaks
| |||
Total # of air leaks | 31 | 28 |
NA
|
Initial # of air leaks/patient | 1.6 (0.7) | 1.6 (0.5) |
1.00
|
# of air leaks/patient after additional treatment | 1.6 (0.6) | 1.4 (0.5) |
0.39
|
Initial grade of air leaks/patient | 1.3 (0.6) | 1.4 (0.5) |
0.77
|
Grade of air leaks/patient after additional treatment | 1.2 (0.4) | 1.1 (0.2) |
0.24
|
PleuraSeal™ application
|
20
| - |
NA
|
Volume of sealant (ml)c
| 2.8 (1.0) | - | - |
Duration (s)c
| 43.0 (17.7) | - | - |
Second application (n) | 1 (5%) | - | - |
Micromyst applicator | 20 (100%) | - | - |
Air leak locations
|
NA
| ||
Staple lines | 7 (23%) | - | - |
Suture lines | 2 (6%) | - | - |
Interfissure area | 16 (52%) | - | - |
Adhesiolysis | 2 (6%) | - | - |
Other manipulation | 4 (13%) | - | - |
Postoperative outcome
Variablea
| Overall | PleuraSeal™ Group | Control Group |
p-valueb
|
---|---|---|---|---|
40 | 20 | 20 | ||
Duration of chest tube (d)
c
, mean (SD) | ||||
Ventral chest tube removal (air leak) | 2.1 (1.2) | 3.9 (3.3) |
0.03
| |
Dorsal chest tube removal (drainage) | 5.1 (4.0) | 5.2 (3.4) |
0.94
| |
Chest tube on suction (h)
c
mean (SD) | 22.9 (1.8) | 49.7 (28.2) |
<0.001
| |
Limiting factor for chest tube removal
| ||||
Air leakage | 8 (20%) | 1 (5%) | 7 (35%) |
0.04
|
Drainage | 32 (80%) | 19 (95%) | 13 (65%) |
0.94
|
Total # of postoperative complications
d
|
21 (52.5%)
|
10 (50%)
|
11 (55%)
|
1.000
|
Bronchogenic fistula | 1 (2.5%) | 0 (0%) | 1 (5%) | |
Chylothorax | 3 (7.5%) | 2 (10%) | 1 (5%) | |
Pneumonia | 6 (15%) | 4 (20%) | 2 (10%) | |
Mechanical Ventilation/ARDS | 1 (2.5%) | 0 (0%) | 1 (5%) | |
Tachyarrhythmia absoluta | 5 (12.5%) | 3 (15%) | 2 (10%) | |
Postoperative severe pain | 4 (10%) | 1 (5%) | 3 (15%) | |
Otherse
| 1 (2.5%) | 0 (0%) | 1 (5%) | |
Length of stay(days)
c
| ||||
Potential hospitalization | 8.2 (4.6) | 10.3 (5.5) | 0.205 | |
Actual hospitalization | 9.9 (3.7) | 11.7 (4.4) | 0.178 |